|Home | About | Journals | Submit | Contact Us | Français|
MARCKS is an actin-binding protein that modulates vascular endothelial cell migration and cytoskeleton signaling (Kalwa, H., and Michel, T. (2011) J. Biol. Chem. 286, 2320–2330). Angiotensin-II is a vasoactive peptide implicated in vascular physiology as well as pathophysiology; the pathways connecting angiotensin-II and cytoskeletal remodeling are incompletely understood. Here we show that MARCKS is expressed in intact arterial preparations, with prominent staining of the endothelium. In endothelial cells, angiotensin-II-promoted MARCKS phosphorylation is abrogated by PEG-catalase, implicating endogenous H2O2 in the angiotensin-II response. Studies using the H2O2 biosensor HyPer2 reveal that angiotensin-II promotes increases in intracellular H2O2. We used a Rac1 FRET biosensor to show that angiotensin-II promotes Rac1 activation that is attenuated by PEG-catalase. siRNA-mediated Rac1 knockdown blocks angiotensin-II-stimulated MARCKS phosphorylation. Cell imaging studies using a phosphoinositide 4,5-bisphosphate (PIP2) biosensor revealed that angiotensin-II PIP2 regulation depends on MARCKS and H2O2. siRNA-mediated knockdown of MARCKS or Rac1 attenuates receptor-mediated activation of the tyrosine kinase c-Abl and disrupts actin fiber formation. These studies establish a critical role for H2O2 in angiotensin-II signaling to the endothelial cytoskeleton in a novel pathway that is critically dependent on MARCKS, Rac1, and c-Abl.
The MARCKS3 (myristoylated alanine-rich C kinase substrate) protein was first described more than 20 years ago as a neuronal phosphoprotein that binds calmodulin (1). The expression of MARCKS has since been documented in many different mammalian cells and tissues (1–6). A general understanding of MARCKS phosphorylation has emerged over the years through analyses of the purified MARCKS protein (1, 3, 8) and studies of MARCKS dynamics in cultured cells (4–7, 9–14). In resting cells, MARCKS associates with the plasma membrane and plasmalemmal caveolae via the protein polybasic domains and by its specific interactions with the signaling phospholipid phosphatidylinositol-(4,5)-diphosphate (PIP2, Refs. 3, 8, 10). Phosphorylation of MARCKS takes place on serine and threonine residues in the protein polybasic domain. Phosphorylated MARCKS undergoes translocation to intracellular sites, where the protein interacts with actin. Phosphorylation of MARCKS also inhibits its binding to calmodulin. The robust and dynamic interactions between MARCKS and these key signaling/structural molecules help to form the basis for the protein broad effects on cellular function. Indeed, the phosphorylation of MARCKS has been implicated in neuronal development (5, 9) and in the migration of vascular endothelial cells (7, 12) and neurons (14). The MARCKSnull knock-out mouse is embryonic lethal (9, 11, 13), and no tissue-specific mouse knock-out models have been described. Much about the receptor-dependent modulation of MARCKS phosphorylation and its implications for vascular cell function remains incompletely understood.
The vasoactive peptide angiotensin-II (Ang-II) has critical roles both in normal vascular physiology as well as in vascular disease states (see reviews in Refs. 15–18). Ang-II has been most extensively characterized in vascular smooth muscle cells, where its effects on vascular tone and oxidative stress are primarily modulated by G protein-coupled AT1 receptors. Less completely characterized are the effects of Ang-II on vascular endothelial cells, where the hormone appears to have both short- and long-term effects on endothelial function. Ang-II appears to modulate endothelial cell motility and to increase the intracellular generation of reactive oxygen species (17, 19). A recent study has implicated the endothelial cell AT1 receptor for Ang-II in the development of aortic aneurysms (20), yet much remains to be learned about the signaling pathways involved in endothelial Ang-II signaling and pathological responses in endothelial cells.
The present studies continue our ongoing exploration of the role of MARCKS in endothelial cell biology. We have previously shown that siRNA-mediated MARCKS knockdown in cultured endothelial cells effectively abrogates directed cell migration and leads to marked changes in the endothelial cytoskeleton (12). These observations have lead to our current studies on the role and regulation of MARCKS in signaling pathways initiated by Ang-II. Activation by Ang-II of the AT1 receptor leads to the stimulation of protein kinase C, one of the key protein kinases that phosphorylates MARCKS (2). Activation of the AT1 receptor also leads to marked changes in cytoskeletal structure and to increases in the intracellular levels of reactive oxygen species (ROS) such as hydrogen peroxide (H2O2, reviewed in Refs. 15–18). ROS have long been characterized as deleterious compounds that are implicated in inflammation, neurodegeneration, and aging (21, 22). It is now clear that the stable ROS H2O2 also plays a central role in physiological signaling pathways in a variety of cells and tissues. The present studies provide evidence for a pathway linking Ang-II-dependent H2O2 generation to MARCKS phosphorylation via a signaling pathway that involves the key cytoskeleton-associated proteins Rac1 and c-Abl. These observations establish new connections between signaling pathways that previously were largely studied in isolation, and provide new insights into the roles of the enigmatic MARCKS protein in the vascular endothelium. These findings may have implications for our understanding of the physiological and pathological responses to Ang-II.
FBS was purchased from HyClone Laboratories. All other cell culture reagents, media, and Lipofectamine 2000 were from Invitrogen. FuGENE 6 transfection reagent was from Roche Applied Science. phorbol 12-myristate 13-acetate was from Calbiochem. Antibodies directed against MARCKS, Phospho MARCKS, phospho c-Abl, Rac1, and vinculin were from cell signaling. Alexa Fluor 488- and Alexa Fluor 568-coupled secondary antibodies and phalloidin/Alexa Fluor 568 were from Invitrogen. SuperSignal chemiluminescence detection reagents and secondary antibodies conjugated with HRP were from Pierce. The FRET biosensor plasmids were the kind gift of Professor Matsuda, University of Kyoto (33). All other reagents were from Sigma.
On the basis of established characteristics of siRNA-targeting constructs, we designed a c-Abl duplex siRNA with the sequence 5′-CAG ACG AAG UGG AAA AGG AdTdT-3′. We used previously characterized and validated duplex siRNA targeting constructs for MARCKS (12) and Rac1 (32). The RNA sequence used as a negative control in siRNA transfections was 5′-GCG CGC UUU GUA GGA UUC G-dTdT-3′. All duplex siRNA-targeting constructs were purchased from Ambion.
Bovine aortic endothelial cells (BAEC) were obtained from Genlantis (San Diego, CA) and maintained in culture in Dulbecco's modified Eagle's medium supplemented with fetal bovine serum (10%, v/v) as described previously. Cells were plated onto gelatin-coated culture dishes and studied prior to cell confluence between passages 6 and 8. siRNA transfections were performed as described previously. Briefly, 24 h after cells were split at a 1:8 ratio, and duplex siRNA constructs (final concentration 30 nm) were transfected using Lipofectamine 2000 (0.15%, v/v), following the protocol provided by the manufacturer. Lipofectamine 2000 was then removed by changing into fresh medium containing 10% FBS 5 h after transfection. Plasmid transfection was carried out with Lipofectamine at a ratio of 1:3 (w/v) according to the manufacturer's protocol. For combined transfections of siRNA-targeting constructs plus plasmid cDNA, the siRNA was transfected first as described above. 5 h after siRNA transfection, the medium was replaced, and the DNA mixture was added and incubated with the cells overnight, at which point the medium was replaced again. Cells were analyzed for a total of 48 h following siRNA transfections.
Angiotensin II was dissolved in H2O and stored at −20 °C. PMA was dissolved in dimethyl sulfoxide and stored at −20 °C. After drug treatments, lysates from BAEC were prepared using a cell lysis buffer (50 mm Tris-HCl, pH 7.4, 150 mm NaCl, 1% Nonidet P-40, 0.025% sodium deoxycholate, 1 mm EDTA, 2 mm Na3VO4, 1 mm NaF, 2 μg/ml leupeptin, 2 μg/ml antipain, 2 μg/ml soybean trypsin inhibitor, and 2 μg/ml lima trypsin inhibitor). Immunoblot analyses of protein expression and phosphorylation were performed as described previously. Detection and quantitation of immunoblots were performed using a ChemiImager HD4000 (AlphaInnotech, San Leandro, CA).
The coding sequence of HyPer2 was cloned into the pWPXL lentiviral expression plasmid downstream of the EF1-α promoter. Recombinant vesicular stomatitis virus-glycoprotein pseudo-typed lentivirus particles were generated in HEK293T cells by transfection of the envelope:packaging:transgene plasmids at a 1:1:1.5 ratio with Fugene6 (Roche) according to the manufacturer's protocol. The viral titer was determined with Lenti-X GoStix (Clontech), and virus particles were concentrated by polyethylene glycol precipitation with PEG-it solution (SBI Bioscience), according to the manufacturer's protocol. The virus pellet was resuspended in PBS and stored at −80 °C. Final titer was determined by serial dilution and fluorescence microscopy.
HyPer2 fluorescence was excited with 420/40 and with 500/16 band-pass excitation filters; corresponding YFP. Emission was acquired every 5 s for 15 min using a 535/30 band-pass emission filter. For calculating HyPer ratio images were acquired; after background subtraction, the HyPer2 signal was quantitated as we and others have previous reported (45). For analyses of fixed cells, BAEC grown on glass-bottomed dishes (Mattek, Boston, MA) or on glass coverslips were treated as indicated, fixed with 4% paraformaldehyde in PBS for 10 min, rinsed with PBS, permeabilized in 0.1% Triton X-100 in PBS for 5 min, and blocked with 10% goat serum in PBS for 1 h. Incubations with primary antibodies were performed in blocking solution for 1 h at room temperature or in the cold room overnight. After washing with PBS, cells were incubated with appropriate secondary antibodies conjugated to immunofluorescent dyes (Alexa Fluor 488 anti-mouse IgG or Alexa Fluor 568 anti-rabbit IgG) in blocking solution for 1 h at room temperature. After washing three times with PBS, cover slips were mounted on slides using medium containing 4′,6-diamidino-2-phenylindole as nuclear counter stain. Microscopic analysis of samples was performed using an Olympus IX81 inverted microscope in conjunction with a DSU spinning disk confocal system equipped with a Hamamatsu Orca ER cooled-CCD camera. Images were acquired using a 100×/1.4 differential interference contrast oil immersion objective lens and analyzed using MetaMorph software (Universal Imaging, Downingtown, PA).
F-Actin was stained with phalloidin/AlexaFluor-568 (InVitrogen, San Diego, CA). Cells were fixed and permeabilized as described above, and then incubated with phalloidin/AlexaFluor-568 (100 nm) for 30 min. Microscopic analysis of samples was performed using an Olympus DSU spinning disk confocal system. Images were acquired using a 60× or 100× differential interference contrast oil immersion objective lens and analyzed using MetaMorph.
All live cell FRET imaging experiments were carried out in HEPES-buffered saline (HBSS, containing 140 mm NaCl, 6 mm KCl, 1.25 mm MgCl2, 2 mm CaCl2, 10 mm HEPES, and 5 mm glucose, pH 7.4. Monitoring of FRET was performed using methods described in detail previously (12, 30, 31, 33, 34, 46, 47). In brief, BAEC were transiently transfected with a plasmid encoding the FRET biosensors. Upon activation, this molecular construct undergoes a structural change that leads to an increase in FRET ratio. Excitation of CFP-PH was at 425 ± 10 nm, and emission was collected at 475 ± 10 (CFP) and 540 ± 10 nm (YFP) using the Semrock FRET-CFP/YFP-B 4-filter single-band set. A series of fluorescence images were taken at 60 s time intervals; visualization and analysis was performed using the MetaMorph FRET module. All FRET construct were kind gifts of Professor Michiyuki Matsuda, Department of Tumor Virology, Research Institute for Microbial Diseases, Kyoto University, Japan.
All experiments were performed at least three times. Mean values for experiments were expressed as mean ± S.E. Statistical differences were assessed by analysis of variance. A p value less than 0.05 was considered statistically significant.
To document the expression of MARCKS in the vascular wall, paraffin sections of murine carotid arteries were stained with a MARCKS-specific antibody and analyzed by fluorescence microscopy (Fig. 1A). The endothelial cell layer was identified by immunostaining with antibodies directed against von Willebrand factor (vWF) and caveolin-1 (Fig. 1B). Robust MARCKS protein staining is seen in the endothelial cell layer, as well as some MARCKS staining in the underlying smooth muscle cells. We next analyzed immunoblots of murine aortic preparations treated ex vivo with Ang-II, and found that Ang-II enhances MARCKS phosphorylation concomitant with an increase in protein kinase C phosphorylation. To further delineate the signaling pathways connecting Ang-II and MARCKS, we pursued studies in cultured endothelial cells using the well-characterized bovine aortic endothelial cells (BAEC) model system. As shown in Fig. 2, A and B, incubation of BAEC with the PKC activator phorbol 12-myristate 13-acetate (PMA) leads to marked increases in MARCKS phosphorylation. Treatment of BAEC with either Ang-II or H2O2 also promotes a striking increase in MARCKS phosphorylation. We next performed dose-response and time course experiments for MARCKS phosphorylation stimulated by H2O2 or Ang-II, and analyzed immunoblots probed with phosphospecific antibodies. These experiments, shown in Fig. 2, document the dose- and time-dependent phosphorylation of MARCKS in response to Ang-II (Fig. 2, E–H) or H2O2 (Fig. 2, I–L). Importantly, the AT1 receptor antagonist losartan blocks Ang-II-induced phosphorylation of MARCKS (Fig. 2, C and D).
These observations help to establish that Ang-II and H2O2 elicit similar effects on MARCKS phosphorylation in endothelial cells. Since Ang-II has been implicated in ROS synthesis in many cell types, we next sought to explore the effects of Ang-II on intracellular H2O2 levels in endothelial cells (17, 23, 24). We used the well-characterized H2O2 biosensor HyPer2 (25–27), which we have previously generated as a recombinant lentiviral construct and used to monitor cellular H2O2 levels (28). We infected BAEC with the HyPer2 lentivirus, and then treated the cells with Ang-II and analyzed the H2O2 response in real time by ratiometric live cell imaging. As shown in Fig. 3, A–C, Ang-II treatment promotes a significant increase in the HyPer2 signal; H2O2 treatment serves as a positive control. These observations provide strong evidence for an Ang-II-promoted increase in endogenous levels of H2O2 in these cells. Further evidence for a central role for endogenous H2O2 in Ang-II-dependent signal transduction comes from experiments using the membrane-permeable H2O2–degrading enzyme PEG-catalase. As shown in Fig. 3, D and E and F and G, after incubating BAEC with PEG-catalase, Ang-II treatment no longer stimulates any increase in MARCKS phosphorylation; again, H2O2 serves as a positive control. In some experiments, PEG-catalase led to a small decrease in basal MARCKS phosphorylation, but this effect was not statistically significant, perhaps reflecting variability in the levels of basal MARCKS phosphorylation in these cells. Taken together, these observations suggest that Ang-II-stimulated H2O2 serves as a key intracellular mediator linking AT1 receptor activation to MARCKS phosphorylation in endothelial cells.
The signaling phospholipid PIP2 is another critical MARCKS binding partner (2, 6, 8, 12, 29). MARCKS phosphorylation leads to the dissociation of MARCKS and PIP2 at the cell membrane (2). We exploited the highly specific PIP2 FRET biosensor PiPi (30, 31) to explore the role of H2O2 in Ang-II-stimulated PIP2 metabolism. The PiPi biosensor changes its fluorescence characteristics in response to alterations in local phospholipid composition. BAEC were transfected with cDNA encoding the PiPi biosensor and the cells were then analyzed by live cell imaging after stimulation with Ang-II. As shown in Fig. 4, Ang-II treatment leads to localized increases in PIP2 at cellular protrusion zones. The Ang-II-promoted increase in localized PIP2 abundance is completely abolished by preincubation of the cells with PEG-catalase (Fig. 4), again implicating H2O2 as a critical determinant of the cellular response to Ang-II.
Alterations in cellular protrusion zones often accompany changes in the activity of cytoskeleton-associated Rho GTPases, particularly Rac1 (31). Moreover, it is well established that Rac1 activity can be enhanced by activation of AT1 receptors (24). To test the involvement of Rac1 in MARCKS signaling in endothelial cells, we “knocked down” Rac1 using a highly specific siRNA targeting construct that we have extensively characterized in BAEC in previous studies (32). siRNA-mediated Rac1 knockdown completely abrogates the MARCKS phosphorylation response seen after angiotensin II or H2O2 stimulation (Fig. 5, A–D). We next explored whether endogenous H2O2 is required for Rac1 activation in experiments using a Rac1 FRET biosensor called Raichu-Rac1 (33–35). We transfected BAEC with Raichu-Rac1 cDNA and then treated these cells with Ang-II; live cell imaging showed that Ang-II promotes a robust increase of the Raichu-Rac1 FRET ratio (Fig. 5, E–G). This Ang-II-promoted increase in Raichu-Rac1 FRET ratio is blocked by PEG-catalase, again indicating a central role for H2O2 in Ang-II-dependent Rac1 activation. Because Rac1 activation can promote marked changes in cytoskeletal structure, we explored the effects of siRNA-mediated Rac1 knockdown on the subcellular localization of MARCKS. MARCKS localization was analyzed in BAEC transfected with a cDNA encoding eGFP-tagged MARCKS. As shown in Fig. 6, MARCKS in resting cells is visualized both in peripheral and internal membranes. Treatment with Ang-II leads to the translocation of MARCKS away from peripheral membranes to intracellular locations, as seen in time lapse images and quantified by monitoring changes in relative fluorescence at the membrane and internal sites (Fig. 6). Live cell imaging of MARCKS localization (Figs. 6, A–D) used wide-field microscopy, whereas confocal imaging approaches were used in the studies of fixed cells (Fig. 6, E–H). After siRNA-mediated Rac1 knockdown, there is an increase in the relative abundance of cytosolic MARCKS, and Ang-II elicits no further change in MARCKS localization. The effects of siRNA-mediated Rac1 knockdown on MARCKS localization were also analyzed using confocal imaging in fixed cells to improve spatial resolution and permit more rigorous quantitation (Fig. 6, E–H); these studies verified the results of live cell imaging.
These findings of Ang-II-modulated regional PIP2 dynamics, Rac1 activation, and MARCKS translocation together strongly implicate cytoskeletal rearrangements as a key component of the Ang-II response. One of the most important steps of cytoskeletal rearrangement is activation of the tyrosine kinase c-Abl (36–39). As shown in Fig. 7, incubation of BAEC with either H2O2 or Ang-II leads to an increase in c-Abl phosphorylation at Tyr-245, a site that has been associated with c-Abl activation (40). The Ang-II- or H2O2-promoted increase in c-Abl phosphorylation is blocked by siRNA-mediated knockdown of either MARCKS or Rac1 (Fig. 7). In contrast, siRNA-mediated knockdown of c-Abl effectively abrogated Ang-II- or H2O2-promoted MARCKS phosphorylation (Fig. 8). Finally, we investigated the role of the cytoskeletal protein vinculin in this pathway. Vinculin directly interacts with PIP2, and vinculin immunostaining serves as a robust marker for the formation of focal adhesion complexes (41). Fig. 9 shows analyses of focal adhesion complex formation in BAEC using confocal imaging to detect vinculin immunofluorescence in combination with phalloidin staining for filamentous actin. Both Ang-II and H2O2 promote a significant increase in focal adhesion sites as well as an increase in cytoskeletal stress fibers. As shown in Fig. 9, after siRNA-mediated knockdown of either Rac1, MARCKS, or cAbl, vinculin staining reveals a disordered pattern of focal adhesion sites, and neither Ang-II nor H2O2 promote a substantive response, in marked contrast to control siRNA-treated cells.
The principal finding of these studies is that Ang-II promotes the H2O2- and Rac1-dependent phosphorylation and translocation of the actin-binding protein MARCKS in vascular endothelial cells, leading to phosphorylation of the c-Abl tyrosine kinase and to cytoskeleton rearrangement (see the model in Fig. 10). We found that MARCKS is expressed and dynamically phosphorylated in the arterial wall, with particularly robust MARCKS expression in the vascular endothelium (Fig. 1). We discovered that MARCKS phosphorylation in cultured vascular endothelial cells is stimulated by Ang-II via the AT1 receptor, as shown by the abrogation of the Ang-II response by the AT1 receptor antagonist losartan (Fig. 2). Our studies have used live cell imaging with highly sensitive and specific biosensors to document the effects of Ang-II on the intracellular accumulation of H2O2 (Fig. 3) and of PIP2 (Fig. 4), and also to establish the Ang-II-dependent activation of the key signaling proteins Rac1 (Figs. 5 and and6)6) and c-Abl (Fig. 7). The intimate connections between these signaling pathways were revealed by studies using well-characterized siRNA targeting constructs to “knock down” Rac1, MARCKS, and c-Abl. These studies revealed that siRNA-mediated Rac1 knockdown effectively abrogated Ang-II signaling to MARCKS (Fig. 5) or c-Abl (Fig. 7). Clearly, there is a dynamic reciprocal relationship between c-Abl and MARCKS, in that siRNA-mediated knockdown of MARCKS attenuates c-Abl phosphorylation, and conversely siRNA-mediated knockdown of c-Abl blocks MARCKS phosphorylation. This interaction between MARCKS and c-Abl may facilitate the coordination of discrete receptor-dependent phosphorylation pathways that modulate key cytoskeleton responses.
These studies have also presented several lines of evidence implicating endogenous H2O2 as the critical determinant of Ang-II-stimulated signaling responses in endothelial cells. Studies using the H2O2 biosensor HyPer2 provide direct evidence that Ang-II leads to an increase in intracellular H2O2 levels (Fig. 3). Experiments exploiting the cell-permeable reagent PEG-modified catalase to degrade intracellular H2O2 showed that PEG-catalase completely abrogates Ang-II-stimulated MARCKS phosphorylation (Fig. 3) as well as the Ang-II-dependent increase in localized PIP2 accumulation (Fig. 4). Activation of the AT1 receptor can lead to localized increases in ROS (17, 24); in turn, ROShave been implicated in rearrangement of the actin cytoskeleton (15, 22). The specific molecular target(s) that modulate the effects of H2O2 on MARCKS-regulated cellular responses have not been identified in these studies. Indeed, there are many H2O2–modulated pathways that could be involved in the altered MARCKS-dependent responses that we have observed following H2O2 treatment. For example, there are many protein kinases and phosphoprotein phosphatases that are regulated by H2O2 (16, 21–23), or the H2O2-dependent oxidation of the MARCKS protein itself might lead to changes in its phosphorylation state and alter signaling to the endothelial cytoskeleton.
The involvement of H2O2 in dynamic actin reorganization and adhesion led us to test the potential role of vinculin in these cells. Vinculin is a highly conserved and abundant protein involved in linking the actin cytoskeleton to the cell membrane at sites of cellular adhesion. At sites of cell adhesion, vinculin plays a role in physiological processes such as cell motility, migration, development, and wound healing (42). Loss of normal vinculin function has been associated with invasive cancer phenotypes, cardiovascular disease states, and derangements in embryogenesis that are also present in the embryonic lethal MARCKS knock-out mouse (9, 11, 42, 43). Importantly, the tail domain of vinculin binds to acidic phospholipids, predominantly PIP2. It has been proposed that PIP2 plays a role in vinculin activation and focal adhesion turnover (44). In control cells stained for vinculin and F-actin, stimulation with Ang-II or H2O2 leads to an increase in focal adhesion complexes and organized fiber formation. The loss of MARCKS, Rac1, or c-Abl, respectively drives the cytoskeleton into a hyperactivated, dysregulated state comparable to agonist stimulation, which then appears to be unresponsive to further increase. This fits nicely into the previous findings, that cells lacking MARCKS having difficulties establishing and stabilizing directed movement (12).
Studies in vascular smooth muscle cells have concluded that the increases in intracellular ROS levels elicited by Ang-II involve the AT1 receptor-dependent activation of NADPH oxidase isoforms involving Rac1 (17, 23). However, the signaling pathways connecting AT1 receptor activation and ROS accumulation in endothelial cells are less well understood. Indeed, our studies in endothelial cells indicate that Rac1 is required for both Ang-II- as well as H2O2-dependent activation of MARCKS phosphorylation (Fig. 5), suggesting that Rac1 is downstream of at least some of the H2O2-modulated signaling responses in these cells (see model in Fig. 10). Rac1 clearly has pleiotropic roles in ROS metabolism. As a subunit of some membrane-targeted NADPH oxidase isoforms, Rac1 can directly participate in the synthesis of superoxide anion. Yet Rac1 is also a critical cytoskeleton regulatory GTPase that regulates key signaling proteins. The present studies have shown that H2O2 modulates Rac1-dependent signaling pathways that lead to MARCKS phosphorylation. The precise H2O2 metabolic pathway(s) that are modulated by Ang-II have not been identified in these studies, but our observations are not compatible with a major role for Rac1-dependent NADPH oxidase isoforms in mediating the Ang-II signaling responses seen in these cells.
Since the original classification of MARCKS as a protein kinase C (PKC) substrate, other protein kinases have also been implicated in MARCKS phosphorylation, including kinases that may themselves be subject to redox regulation. The increase in intracellular H2O2 that we observed following AT1 receptor activation may reflect either an increase in H2O2 synthesis or a decrease in H2O2 degradation. The candidate enzymes include a broad range of differentially targeted signaling proteins that are involved in H2O2 metabolism, and which provide an alternative pathway for the receptor-dependent control of protein phosphorylation responses.
These studies provide new evidence for important links between signaling pathways that have largely been studied in isolation in previous reports. For example, the connections between Ang-II and ROS generation have been extensively characterized, but the critical involvement of MARCKS has not been previously appreciated. A connection between Ang-II and Rac1 activation has been observed, but the critical role for H2O2 in this pathway has not been previously described. The activation of MARCKS by receptor-regulated kinase pathways has been explored in earlier studies, but the involvement of neither Rac1 nor H2O2 in the MARCKS phosphorylation response has been previously reported. Thus, the present studies represent a synthesis of signaling pathways that previously were studied pairwise to now reveal distinctive features of an integrated signaling pathway that identify important new aspects of the vascular response to Ang-II.
Ang-II has been clearly implicated in vascular pathology, and drugs modulating angiotensin metabolism and angiotensin action are critical components in the therapeutic armamentarium for cardiovascular disease. The present studies have helped to establish that Ang-II and MARCKS are critical determinants of focal adhesion complex formation in cultured endothelial cells. It has long been known that Ang-II infusion in mice leads to the formation of aortic aneurysms (17), and a recent report showed that Ang-II-promoted aneurysm formation is attenuated in knock-out mice following targeted inactivation of the AT1 receptor specifically in vascular endothelial cells (20).
Our work has provided evidence for a signaling pathway in endothelial cells in which stimulation of the AT1 receptor leads to the elevation of intracellular H2O2 levels and to activation of the small GTPase Rac1, which are required for the subsequent phosphorylation and translocation of MARCKS, leading to an increase in localized PIP2 levels and to the activation of kinase c-Abl, which is required for the recruitment of the PIP2-sensitive protein vinculin, and lead ultimately to marked effects on cytoskeletal structure and cell adhesion. These observations that Ang-II and MARCKS so profoundly affect the cytoskeleton of aortic endothelial cells may provide a plausible mechanistic basis for understanding the derangements in Ang-II responses that lead to aneurysm formation. Further study of these pathways may lead to the identification of new sites for pharmacological intervention in disease states involving the vascular wall.
We thank Ben Jin, PhD for developing and validating the c-Abl siRNA and for performing initial studies on the effects of H2O2 on MARCKS phosphorylation. We thank Perry Blackshear (NIEHS) for providing us with MARCKS cDNA constructs, and are grateful to Professor Michiyuki Matsuda (Kyoto University) for providing us with FRET biosensor plasmids.
*This work was supported, in whole or in part, by National Institutes of Health Grants HL46457, HL48743, and GM36259 (to T. M.).
3The abbreviations used are: